New venture explores frontiers of personalized medicine

Oct 26, 2010

Pharmaceuticals that seek out cancerous cells and deliver treatments to them; imaging techniques that can help doctors detect diseases before the physical signs begin to appear; and medicines that are tailor-made for individual patients, are within the sights of an exciting new Australian start-up venture.

Clarity Pharmaceuticals Pty Ltd is a new venture, which could lead to a revolution in the future of and treatment.

To launch the company, Clarity has secured licences to technology developed by the University of Melbourne and the Australian Nuclear Science and Technology Organisation (ANSTO).

Dr Matt Harris, Managing Director of TM Ventures says the basis of Clarity Pharmaceuticals is exciting new compounds developed by scientists from ANSTO and the University of Melbourne for use in positron (PET).

"PET is the fastest growing modality. Whilst tests such as X-ray and MRI provide information on anatomy and structure, PET uses the movement of radiopharmaceuticals through the body to examine metabolic processes, such as heart and in real time," he said.

"Based on foundational research undertaken by the University of Melbourne and ANSTO, Clarity Pharmaceuticals is the future of personalised medicine."

Research teams from both the University of Melbourne and ANSTO have developed new compounds that significantly improve the accuracy of .

These compounds can also be used in treatment to target therapeutics to specific disease sites and then to accurately monitor how well that treatment is working.

"These agents are targeted to selectively illuminate diseased tissue. The new compounds have the potential to provide clinicians with valuable diagnostic information to guide, improve and assess treatment regimes," said Dr Paul Donnelly from the University of Melbourne's School of Chemistry.

"Using PET images, doctors will have the potential to improve diagnosis and provide a personal prognosis. Ongoing monitoring using PET will determine progress and enable the refining of treatment options," he said.

According to ANSTO General Manager of Business Development, Rosanne Robinson, this exciting venture will enable even wider community accessibility to PET technology with great outcomes.

"For patients with cancer, this treatment could be revolutionary. No longer would patients suffer from the terrible side effects of chemotherapy because treatment could be precise, targeted and effective," she said.

In addition, the high calibre of research from which Clarity Pharmaceuticals has been founded, was acknowledged by the Victorian Government through the awarding of a Victoria Fellowship to a member of Dr Donnelly's research team, Dr Michelle Ma.

Explore further: Strategies can help docs lower their tax burden

add to favorites email to friend print save as pdf

Related Stories

New tracer for better melanoma image

Oct 06, 2009

The Australian research published this week in the American Chemical Society's Journal of Medicinal Chemistry describes a new radiopharmaceutical tracer that promises to give clearer pictures of melanoma and could lead t ...

New scans improve treatment accuracy

Sep 14, 2006

Australian doctors say they have developed new scans that can that quickly show whether breast cancer cells are responding to therapy.

Medical imaging benefits far outweigh radiation risks

Mar 06, 2009

In response to a recent report by the National Council on Radiation Protection and Measurement (NCRP) stating that the U.S. population is exposed to seven times more radiation from medical imaging exams than in 1980, SNM ...

Recommended for you

The human race evolved to be fair for selfish reasons

Sep 19, 2014

"Make sure you play fairly," often say parents to their kids. In fact, children do not need encouragement to be fair, it is a unique feature of human social life, which emerges in childhood. When given the o ...

Non-stop PET/CT scan provides accurate images

Sep 18, 2014

Siemens is improving PET/CT imaging and data quality while reducing radiation exposure. The Biograph mCT Flow PET/CT scanner is a new positron emission tomography/computed tomography (PET/CT) system that, ...

Experts: Chopin's heart shows signs of TB

Sep 17, 2014

The preserved heart of composer Frederic Chopin contains signs of tuberculosis and possibly some other lung disease, medical experts said Wednesday.

User comments : 0